TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03440593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric delivery will target results of IC measurement.
Description: The prescribed calories to be delivered will be set to target the measurement obtained from performing indirect calorimetry (IC). IC measures the gas exchange of oxygen consumption and carbon dioxide production to determine the true metabolic needs for cellular respiration. The expenditure of calories will be measured utilizing the gas module incorporated within the General Electric Carescape R860 ventilators.
Study: NCT03223571

Intervention type: OTHER
Intervention: Motor rehabilitation training
Description: Post-stroke participants receive 6 week of rehabilitation training of the paretic upper-limb.
Study: NCT01868360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjunctival aflibercept
Description: subconjunctival aflibercept injection
Study: NCT03005184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 200 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 200 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 200 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 200 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 200 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 200 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 200 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 200 mg bid
Description: oral medication
Study: NCT01868360

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Standard of care only
Description: Patients will receive standard of care (steroids and cyclosporine) treatment only.
Study: NCT03005184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 200 mg bid
Description: oral medication
Study: NCT02388620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: 400 mg
Study: NCT00912119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epsilon-Aminocaproic Acid
Description: Group A (low dose) will receive a loading dose of EACA of 25 mg/kg over ten minutes followed by a continuous EACA infusion at 10 mg/kg/hr, which will be continued until the end of surgery
Study: NCT03550560

Intervention type: PROCEDURE
Intervention: EUS-Guided drainage
Description: Drainage of refractory malignant ascites by endoscopic ultrasound-guided (EUS-Guided) implantation of plastic prostheses.
Study: NCT01404663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD133 stem cell injection
Description: Bone marrow derived CD133 stem cell witch are transplanted by intrathecal injection
Study: NCT03327233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connecare self managment system
Description: The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
Study: NCT02597062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT03005184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 200 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 200 mg bid
Description: oral medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 200 mg bid
Description: oral medication
Study: NCT02924883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Trastuzumab emtansine 3.6 mg/kg IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab emtansine
Description: Trastuzumab emtansine 3.6 mg/kg IV infusion
Study: NCT03005184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous medication
Study: NCT02924883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to atezolizumab
Study: NCT03005184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous medication
Study: NCT02924883

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matched to atezolizumab
Study: NCT04272060

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT angiography
Description: Diagnostic CT angiography

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Invasive coronary angiography
Description: Diagnostic invasive coronary angiography
Study: NCT00445003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection of 0.5 mg ranibizumab at baseline and 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Intravitreal injection of 4 mg triamcinolone acetonide at baseline and sham injection at 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham injection
Description: Sham injection at baseline and 4 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal/grid laser
Description: Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Focal/grid laser
Description: Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal/grid laser
Description: Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
Study: NCT03005184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous medication
Study: NCT00832832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eyelid closure
Description: Eyelid will be closed after eye drop instillation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention will be assigned
Description: No intervention will be assigned to this arm
Study: NCT04962256

Intervention type: PROCEDURE
Intervention: Enhanced recovery after surgery
Description: ERAS management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
Study: NCT04645121

Intervention type: DEVICE
Intervention: Carbon Monoxide-based Rebreathing
Description: 6 minutes Carbon Monoxide-based Rebreathing that estimate blood volume, plasma volume and erythrocyte volume.

Intervention type: DEVICE
Intervention: Carbon Monoxide-based Rebreathing
Description: 6 minutes Carbon Monoxide-based Rebreathing that estimate blood volume, plasma volume and erythrocyte volume.
Study: NCT01987011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1109

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03568565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePREP Program
Description: see arm descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePREP Program
Description: see arm descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OurRelationship Program
Description: see arm descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OurRelationship Program
Description: see arm descriptions
Study: NCT04321850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate 50 Mg Tab
Description: The tablets were manufactured specifically for this study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: The tablets were manufactured specifically for this study.
Study: NCT01837654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plantarflexion 2nd wave
Description: At the beginning of the 2nd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plantarflexion - 3rd wave
Description: At the beginning of the 3rd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
Study: NCT02845739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kidney transplanted patients
Study: NCT01141426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Short-term Dynamic Psychotherapy
Description: The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Secondary Care Treatment as Usual
Description: At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
Study: NCT02587871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo microtransplant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Allogeneic Lymphocytes
Description: Undergo microtransplant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF mobilized peripheral blood cells
Description: microtransplantation
Study: NCT04584268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness
Description: in person and smart phone application mindfulness practice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard medical education
Description: standard medical education / control
Study: NCT02039908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.
Study: NCT03455348

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: catheter insertion
Description: catheter insertion one to less than 4 four centimeters to the wrist joint (Group A) and the other, to more than four centimeters to the wrist joint. (Group B)
Study: NCT04645121

Intervention type: DEVICE
Intervention: Bioimpedance
Description: Measures total volume, intra and extracellular volume.

Intervention type: DEVICE
Intervention: Bioimpedance
Description: Measures total volume, intra and extracellular volume.
Study: NCT06774716

Intervention type: BEHAVIORAL
Intervention: Internet-based cognitive behavioural treatment and relapse prevention
Description: A self help program consisting of 12 modules and access to therapist guidance through messages. Including three video session.

Intervention type: BEHAVIORAL
Intervention: Face-to-face cognitive behavioural treatment or short-term psycodynamic therapy with relapse prevention
Description: Face-to-face therapy with a licenced psychologist or licenced psychotherapist, including 10-15 sessions.
Study: NCT06772883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sexual education and counseling
Description: The women included in the Working Group were contacted by phone and invited to the hospital. Sexual education and counseling were provided in accordance with the PLISSIT model. A total of 5 interviews were conducted with the women, the first face-to-face interview and the subsequent ones by telephone. FSFI assessments in the study FSFI assessments were performed 5 times (initial, 1st, 3rd, 6th months and 1 year later). According to the PLISSIT model, their sexuality and any problems since the previous assessment were discussed and a short counseling was given if necessary.

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: routine clinical care
Study: NCT03451851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive a weight-based dose of guselkumab subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guselkumab
Description: Participants will receive a weight-based dose of guselkumab subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guselkumab
Description: Participants will receive a weight-based dose of guselkumab subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive a weight-based dose of guselkumab subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for guselkumab
Description: Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for guselkumab
Description: Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Participants will receive a weight-based dose of etanercept (up to 50 mg) subcutaneously.
Study: NCT04118894

Intervention type: DEVICE
Intervention: Foot and Ankle Devices
Description: Wright devices used in foot and ankle procedures
Study: NCT04645121

Intervention type: RADIATION
Intervention: Radioactive labelling of erythrocytes and albumin
Description: Measure blood volume, plasma volume and erythrocyte volume.

Intervention type: RADIATION
Intervention: Radioactive labelling of erythrocytes and albumin
Description: Measure blood volume, plasma volume and erythrocyte volume.
Study: NCT02991664

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Equia Forte
Description: Glass ionomer restorative system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: G-aenial Posterior
Description: Micro hybrid composite resin
Study: NCT04276727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MINT study IMP
Description: Application of gel for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MINT study IMP
Description: Application of gel for 6 weeks.
Study: NCT04371302

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire
Description: Assessment of demographics, burnout, depression and self-perceived medical errors
Study: NCT04375657

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TRIIM Treatment
Description: Personalized combination of somatropin, metformin, and DHEA

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Metformin and DHEA
Study: NCT00428584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Formulation of rebif - human interferon beta-1a
Description: New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta -1b
Description: Betaseron - 250 mcg, SC (sub-cutaneous) every other day injection.
Study: NCT04320758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional preparation design
Description: chamfer finish line

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biologically oriented preparation technique
Description: shoulder less preparation design
Study: NCT01853618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 3.5 mg/kg or 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 3.5 mg/kg or 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 3.5 mg/kg or 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 3.5 mg/kg or 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 3.5 mg/kg or 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 3.5 mg/kg or 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Performed on Day 36

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Performed on Day 36

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Performed on Day 36

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Performed on Day 36

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Performed on Day 36